GlassScriptPhysician profile
Toby M Bond
NPI 1467463513
$14,527.10
in general payments reported to CMS, 2019-2025
63 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $2,341 · 2021: $2,022 · 2022: $2,312 · 2023: $2,148 · 2024: $1,976 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,883 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,882.58 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,506.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,919.23 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $1,592.81 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $975.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $850.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $668.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.93 | 2019-2025 | Jardiance |
| Pfizer INC. | $527.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $421.44 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.89 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $323.08 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $311.35 | 2019-2025 | Austedo Xr |
| Astellas Pharma US INC | $284.09 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $212.04 | 2022-2025 | |
| Allergan, INC. | $204.10 | 2019-2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.